The PARP inhibitor olaparib induces CD8+ T cell infiltration and activation in vivo through activation of the cGAS/STING pathway in tumor cells with paracrine activation of dendritic cells and was more significant in HR-deficient than in HR-proficient breast cancer cells [43]. This evidence concerns the gene STING1 and neoplasm.